Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further ...

Nadunolimab is a fully humanized Fc-enhanced IgG1 monoclonal antibody targeting interleukin 1 receptor accessory protein.

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further devel ...

In a new study, researchers at örebro University have demonstrated that it is possible to influence inflammation in the blood vessels by blocking a specific protein, IL1RAP. This protein acts as ...

CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines of the IL-1-super family: IL-1, IL-33 and IL-36. CAN10 is ...

The current study shows the potential of interleukin-1 receptor accessory protein (IL1RAP) as a target for ADC therapy across a broad spectrum of cancers.The poster is presented at the American ...

LUND, SWEDEN / ACCESS Newswire / April 25, 2025 / Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today released a poster with new preclinical data that strengthens the rationale behind the ...

Cantargia's IL1RAP ADCs exploit IL1RAP expression by tumor cells and other cells in the tumor microenvironment (TME) to deliver toxic drugs into the tumor. The findings demonstrated safety ...

A key finding is that pancreatic cancer (PDAC) patients with high tumor levels of IL1RAP, the target of nadunolimab, benefit most from nadunolimab combined with chemotherapy. This further ...